Skip to main content
  • Home
  • Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Topic:
  • Heart Failure

Available Credit:

  • 1.00 MMA

Course Published On:

Course Expiry Date:

Overview

This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.

 

The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.

 

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

Disclosure

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

 

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Learning Objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
Register now Log in

Module

Title

Duration

Speakers

1 Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
2 Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
3 Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs) Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)
4a Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4b Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action James Januzzi (Massachusetts General Hospital, US) Akshay Desai (Brigham and Women’s Hospital, Boston, MA, US) Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4c Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)
4d Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)
4e Clinical questions on ARNI therapy – Chapter 5: Summary Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
1.

Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)

3.

Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)

4a.

Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

4c.

Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)

4d.

Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)

4e.

Clinical questions on ARNI therapy – Chapter 5: Summary

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

Speaker

Wan Azman Wan Ahmad

Prof Wan Azman Wan Ahmad is Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia. He graduated from University of Malaya in 1983 and currently serves as President of the National Heart Association of Malaysia.

View full profile

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore

Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction.

View full profile

Azmee Mohd Ghazi

National Heart Institute, Kuala Lumpur, MY

Dr Azmee Mohd Ghazi is a Cardiologist at the National Heart Centre, Malaysia, where he serves as Clinical Director for Heart Failure and Heart Transplant.

View full profile

James Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

David Morrow

Cardiovascular Division, Brisham and Women’s Hospital

Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program

View full profile

Rolf Wachter

University of Leipzig, Leipzig, Germany

Prof Rolf Wachter is Director of Cardiology at the Clinic and Policlinic for Cardiology, University Hospital Leipzig. Prior to this, he served as Deputy Director (Leitender Oberarzt), Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany.

View full profile

AVAILABLE CREDIT

1.00 Malaysian Medical Association (MMA)

Related Courses

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
  • 0.75 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
  • 0.50 AMA PRA Credit

Learning objectives

  • Identify patients likely to benefit from invasive procedures versus pharmacological treatment
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments
See more
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
  • 1.00 MMA

Learning objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
A Review of Emerging ARNI Data in HFrEF
  • 1.00 EBAC

Learning objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Optimising Treatment of HF
  • 1.00 (EBAC)

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
See more
Heart Failure & Cardiomyopathy: Highlights 2019-2021
  • 0.25 AMA PRA Category 1 Credit™

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
See more